Penserra Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Penserra Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.93M	Sell	30,226 -22,876	-43%	-$1.19M	0.01%	371
2026 Q1	$2.56M	Buy	+53,102	New	+$2.35M	0.03%	316
2021 Q4	–	Sell	-745	Closed	-$8K	–	1456
2021 Q3	$8K	Buy	745 +10	+1%	+$130	﹤0.01%	1380
2021 Q2	$10K	Buy	735 +15	+2%	+$228	﹤0.01%	1272
2021 Q1	$13K	Sell	720 -20	-3%	-$409	﹤0.01%	1007
2020 Q4	$13K	Buy	+740	New	+$13K	﹤0.01%	899

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Penserra Capital Management's KNSA Position: Q2 2026 in Review

Penserra Capital Management reduced its Kiniksa Pharmaceuticals (KNSA) stake by 43% in Q2 2026, selling an estimated $1.19M and leaving 30,226 shares worth $1.93M. The position accounts for 0.01% of the portfolio, ranked #371.

Penserra Capital Management first reported a position in KNSA in Q4 2020 and has held it in 6 quarters since. The position peaked at $2.56M in Q1 2026. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Penserra Capital Management held 30,226 shares of Kiniksa Pharmaceuticals worth $1.93M as of Q2 2026.
Penserra Capital Management sold 22,876 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $1.19M.
Kiniksa Pharmaceuticals made up 0.01% of Penserra Capital Management's portfolio in Q2 2026, its #371 holding.
Penserra Capital Management first reported a position in Kiniksa Pharmaceuticals in Q4 2020 and has held it in 6 quarters since.
Penserra Capital Management's Kiniksa Pharmaceuticals position peaked at $2.56M in Q1 2026.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.